Virus-specific T cells can recognize allogeneic HLA (allo-HLA) through TCR cross-reactivity. The allospecificity often differs by individual (private cross-reactivity) but also can be shared by multiple individuals (public crossreactivity); however, only a few examples of the latter have been described. Because these could facilitate alloreactivity prediction in transplantation, we aimed to identify novel public cross-reactivities of human virusspecific CD8 + T cells directed against allo-HLA by assessing their reactivity in mixed-lymphocyte reactions. Further characterization was done by studying TCR usage with primer-based DNA sequencing, cytokine production with ELISAs, and cytotoxicity with 51 chromium-release assays. We identified three novel public allo-HLA cross-reactivities of human virus-specific . Cross-reactivity was tested against different cell types including endothelial and epithelial cells. All cross-reactive T cells expressed a memory phenotype, emphasizing the importance for transplantation. We conclude that public allo-HLA cross-reactivity of virus-specific memory T cells is not uncommon and may create novel opportunities for alloreactivity prediction and risk estimation in transplantation.
Introduction
Alloreactive T cells are a major cause of graft loss after solid organ transplantation and acute graft-versushost disease after hematopoietic stem cell transplantation (1, 2) . In particular alloreactive T cells expressing a memory phenotype are a potential threat, since their activation threshold is substantially lower compared with their na€ ıve counterpart while their effector function is enhanced (3, 4) . Interestingly, alloreactive memory T cells are present in all individuals, even without prior exposure to alloantigen. This can be explained by heterologous immunity of virus-specific T cells: the inherent capacity of TCRs to cross-react with multiple antigens. Heterologous immunity thereby arms virusspecific T cells with a TCR that can recognize a range of related and unrelated viral peptides, creating a survival benefit to the host. This scenario describes the recognition of different peptides presented by a self HLA. TCR cross-reactivity, however, can also be directed against allogeneic HLA (allo-HLA). Consequently, memory T cells that are primed by viral infections may contribute to allograft rejection. Alarmingly, such TCR cross-reactivity of virus-specific memory T cells against allogeneic HLA is indeed common (5) .
The TCR repertoire differs by individual due to both intrinsic (thymic selection) and extrinsic (allergens/viral infections) factors. Although most TCRs appear to be unique to individuals (private TCRs), dominant TCR sequences have also been found in multiple individuals (public TCRs). Public TCRs are selected for optimal recognition of immunodominant viral epitopes (6) , and cytomegalovirus (CMV) and Epstein-Barr virus (EBV) in particular are known for inducing public TCR responses (7) (8) (9) . Inherent to their structural differences, the allospecificity of crossreactive private TCRs (even with the same viral specificity) is directed toward different alloepitopes (private cross-reactivity) (10) , and thus alloreactivity by private TCR cross-reactivity is impossible to predict. In contrast, cross-reactivity of public TCRs is directed against the same alloepitopes in multiple individuals and thus could facilitate the prediction of alloreactivity by memory T cells. A classic example of such public cross-reactivity is found in HLA-B8 + individuals: When infected with the EBV virus, they select a public TCR that, in addition to the viral epitope (HLA-B8/FLR), recognizes allogeneic HLA-B*44:02 (11) . Such cross-reactive virus-specific T cells were also identified in HLA-B8 + B44 À lung-transplant recipients transplanted with an HLA-B*44:02 graft (12, 13) .
To date, public cross-reactivity of virus-specific T cells is considered uncommon because it requires strict TCR preservation in unrelated individuals; however, reports of other TCR cross-reactivities with similar allospecificity in unrelated individuals give reason to challenge this conception (14) (15) (16) (17) . Furthermore, Nguyen et al recently identified cross-reactivity of CMV A2/NLV-specific T cells with nearly identical TCR usage against HLA-B27 in two unrelated individuals (18) .
To the best of our knowledge, these indications of public cross-reactivity of virus-specific T cells are the only ones described so far. Identification of additional public crossreactivities of virus-specific T cells and knowledge concerning their prevalence and functional characteristics could enable monitoring and facilitate risk estimation in a transplantation setting. Therefore, we aimed to identify novel public cross-reactivities of virus-specific CD8 + memory T cells directed against allogeneic HLA antigens.
Materials and Methods

Collection of responder and target cells
Responder and target peripheral blood mononuclear cells (PBMCs) were derived from healthy donors with informed consent in accordance with the Declaration of Helsinki. PBMCs were isolated from whole blood by standard density gradient centrifugation (Ficoll-Isopaque separation) and cryopreserved until usage.
EBV-transformed lymphoblastoid cell lines (EBV-LCLs) were generated according to standard protocol. Supernatant of the EBV-producing marmoset cell line B95.8 was added to bulk PBMCs, incubated for 1.5 h at 37°C, and cultured in RPMI 1640 medium (Gibco, Carlsbad, CA) supplemented with 10% fetal calf serum (FCS), penicillin/streptavidin and glutamine.
Phytohemagglutinin (PHA) blasts were generated from PBMCs by culturing in RPMI 1640 medium (Gibco) supplemented with penicillin/streptavidin, glutamine, 15% human serum (HS), and PHA (4 lg/mL; Murex Biotech Ltd).
Human umbilical vein endothelial cells (HUVECs) were cultured in M199 medium (Gibco) supplemented with 10% FCS, sodium pyruvate (Gibco), penicillin/streptavidin (Gibco), and 0.01% b-mercaptoethanol (0.05M; Sigma Aldrich, St. Louis, MO). HUVECs were used at passages 1-4.
Proximal tubular epithelial cells (PTECs) were cultured in Dulbecco's Modified Eagle's Medium and Ham's F-12 Nutrient Mixture (Lonza, Basel, Switzerland) supplemented with 26 lg/mL hydrocortisone (SigmaAldrich), 1% 19 insulin-transferrin-sodium selenite media supplement (Sigma-Aldrich), 10 lg/mL human epidermal growth factor (SigmaAldrich), 0.08 pg/mL 3,3 0 ,5-triiodo-L-thyronine sodium salt (Sigma-Aldrich), and penicillin/streptavidin (Gibco). PTECs were used at passages 1-4.
HLA typing was achieved by sequence-specific oligonucleotide (SSO) and sequence-specific primer (SSP) genotyping at the European Federation of Immunogenetics-accredited national reference laboratory for histocompatibility testing at the Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, the Netherlands. 
Proliferation assays
Generation of virus-specific CD8 + T cell clones
Virus-specific CD8 + memory T cell clones were generated by fluorescence-activated cell sorting (FACS; FACSAria; BD Biosciences), as described previously (19) . PBMCs of healthy donors were stained with PE-labeled viral tetramers CMV pp65(123-131) HLA-B*35:01/IPSINVHHY (CMV B35/IPS), influenza (FLU) IMP(58-66) HLA-A*02:01/GILGFVFTL (FLU A2/GIL), and varicella zoster virus (VZV) IE62(593-601) HLA-A*02:01/ ALWALPHAA (VZV A2/ALW; protein facility of the Leiden University Medical Center) and fluorescein isothiocyanate-labeled mAb against CD4, CD19, CD45-RA, CD14, CD40, CD16, and CD56 (BD Pharmingen, San Diego, CA). The FL1 channel was used as a dump channel to avoid direct CD8 mAb staining, as simultaneous CD8/MHC staining triggers TCR internalization. TCR usage was determined by primer-based DNA sequencing using primers against the Vb and Va alleles (20) .
For optimal conditioning, CD8 + T cell clones were cultured with irradiated PBMCs (4000 rad) from anonymous buffy coats (Sanquin; Leiden, the Netherlands) 8 days prior to functional testing.
Cytokine production assays
Interferon c (IFN-c) production of CD8 + T cell clones was measured by ELISA according to the manufacturer's protocol (U-CyTech ELISA kit; UCyTech, Utrecht, the Netherlands). Overall, 5 9 10 3 CD8 + T cells were stimulated with 5 9 10 4 EBV-LCLs for 24 h at 37°C in IMDM (Lonza)
supplemented with penicillin/streptavidin, glutamine, 5% FCS (Lonza), 5% HS, and IL-2 (10 U/mL) in triplicate wells.
Cytotoxicity assay
Cytotoxicity was determined by 51 chromium ( 51 Cr)-release assay, as previously described (19, 21) . In short, CD8 + T cell clones were stimulated with 51 Cr-labeled PHA blasts, EBV-LCLs, PTECs, and HUVECs for 4 h at 37°C in IMDM (Lonza) supplemented with penicillin/streptavidin, glutamine, 5% FCS (Lonza), 5% HS, and IL-2 (10 U/mL). 51 Cr release was measured on a 
Results
Virus-specific CD8 + T cells from different individuals proliferate in response to the same allo-HLA antigens A cohort comprising 30 healthy individuals was screened for allo-HLA reactivity of virus-specific CD8 + T cells in MLRs against a panel of stimulators expressing the most frequent HLA class I antigens (>5%) in the Western population. In multiple responders, CD8 + T cells with the same viral specificity showed a similar proliferative pattern against the panel (Table 1) Shared allo-HLA cross-reactivity is assigned to public TCR usage of virus-specific CD8 + memory T cells CMV B35/IPS-, FLU A2/GIL-, and VZV A2/ALW-specific CD8 + memory T cell clones were generated from the individuals that showed proliferation in response to identical allo-HLA antigens, and highly conserved TCR Va and Vb usage was observed. Remarkably, the TCR usage of CMV B35/IPS-and FLU A2/GIL-specific T cell clones derived from individuals also expressing the cross-reactive HLA antigen highly resembled the TCR usage of allo-HLA cross-reactive T cell clones. Only minor amino acid differences within the CDR3a (FLU A2/GIL) and CDR3b (CMV B35/IPS) regions were able to abrogate the occurrence of cross-reactivity (Table 2 , Data S2).
Stimulation with allogeneic PBMCs confirmed that T cell clones expressing public TCRs were able to proliferate in response to the cross-reactive alloantigen. Allorecognition of HLA-B51, in contrast to HLA-B58, induced robust proliferation of cross-reactive CMV B35/ IPS T cells, similar to stronger compared with cognate antigen (B35 plus IPS). Allorecognition of HLA-B38 also induced comparable proliferation of cross-reactive FLU A2/GIL T cells as cognate antigen (A2 plus GIL), whereas HLA-B55 allorecognition induced less pronounced proliferation of VZV A2/ALW T cells compared with cognate antigen (A2 plus ALW). T cell clones derived from individuals that also expressed the cross- reactive HLA antigen (CMV B35/IPS 8A2, FLU A2/ GIL 4A2) did not proliferate in response to syngeneic cross-reactive HLA. Of interest, HLA-B38 allorecognition of FLU A2/GIL T cells was hampered by differences in Va usage (FLU A2/GIL 3F8) and even in CDR3a usage alone (FLU A2/GIL 4A2) ( Figure 2) .
A B
Virus-specific CD8 + memory T cell clones with public cross-reactive TCRs produce IFN-c on stimulation with allogeneic targets IFN-c production of the T cell clones was determined by ELISAs. CMV B35/IPS-, FLU A2/GIL-, and VZV A2/ALWspecific CD8 + memory T cell clones bearing public TCRs produced IFN-c in response to EBV-LCLs expressing self-HLA and viral peptide and EBV-LCLs expressing crossreactive allo-HLA antigens. Interestingly, minor HLA-B57 cross-reactivity was observed for HLA-B58 cross-reactive CMV B35/IPS T cells ( Figure 3A and 3B), whereas no significant proliferation against HLA-B57 was observed in MLR at the bulk or clonal level (data not shown; Figure 2) . Cross-reactive FLU A2/GIL T cell clones produced IFN-c mainly on HLA-B*38:01 allorecognition, whereas HLA-B*38:02 allorecognition resulted in only limited IFNc production. FLU A2/GIL T cell clones with the same Vb but different Va usage did not cross-react against HLA-B38. Cross-reactive VZV A2/ALW T cell clone 1C12 produced IFN-c on HLA-B55 + allorecognition, comparable to VZV A2/ALW T cell clone 12, as published previously (22) . Furthermore, despite highly similar TCR usage, virus-specific T cells isolated from individuals carrying cross-reactive HLA antigens did not produce IFN-c when stimulated with syngeneic HLA. Interestingly, CMV B35/ IPS T cell clone 8A2 (derived from the heterozygous HLA-B35 + B51 + individual that showed minor proliferation in response to HLA-B58) produced high levels of IFN-c on recognition of HLA-B58 + EBV-LCLs and limited levels on recognition of HLA-B57 + EBV-LCLs ( Figure 3B ). Heat maps of the IFN-c ELISAs are included in Data S1, and the allospecificity of all T cell clones is indicated in Table 2 . + PHA blasts, EBV-LCLs, PTECs, and HUVECs. Finally, FLU A2/GIL T cell clones generated from the HLA-A2 + B38 + individual again showed no recognition of HLA-B38 + targets (Figure 4B) . Cytotoxicity results of the T cell clones that were able to lyse target cells expressing the cross-reactive HLA antigen are summarized in Table 3 .
Discussion
Because public cross-reactivity hinges on strict TCR preservation in multiple individuals, it is allegedly uncommon. Nevertheless, using a small cohort and a restricted set of viral tetramers, we were able to identify three novel public allo-HLA cross-reactivities of virus-specific memory T cells. All TCRs of HLA-B51-and HLA-B58/57-cross-reactive CMV B35/IPS T cells shared strong public features (9) , and only minor amino acid differences within their CDR3 loops differentiated (24, 25) . Although public TCR usage has not been described for VZV A2/ALW-specific T cells, CD8 + T cell responses against the VZV A2/ALW epitope are shared by the majority of HLA-A2 + individuals (26) , and HLA-B55 cross-reactivity of VZV A2/ALWspecific T cells with corresponding TCR Vb usage has in fact been identified previously in yet another individual (5) . The nearly identical TCR usage in three unrelated individuals again firmly points toward the involvement of a public TCR.
FLU A2/GIL and CMV B35/IPS T cells sorted from HLA-A2
+ B38 + and HLA-B35 + B51 + individuals, respectively, did not recognize HLA-B38 and HLA-B51 alloantigens, which is likely the result of thymic TCR selection to avoid autoimmunity. This confirms the observation in HLA-B8 + B*44:02 + heterozygous individuals, which select oligoclonal EBV B8/FLR TCRs that are completely disparate from the public HLA-B*44:02-cross-reactive TCR (27, 28) . Furthermore, even individuals heterozygous for HLA-B*08:01 and HLA-B*44:03 (which highly resembles HLA-B*44:02 but is not functionally cross-reactive) select EBV B8/FLR TCRs that are highly distinct from the public HLA-B*44:02 cross-reactive TCR (29) . In contrast, we did not find such cautious TCR selection. First, unlike HLA-B*44:03 skewing of the EBV B8/FLR TCR repertoire, self expression of HLA-B51 did not abrogate HLA-B58 crossreactivity of CMV B35/IPS cross-reactive T cells in a heterozygous HLA-B35 + B51 + individual. Moreover, FLU A2/GIL and CMV B35/IPS TCRs from HLA-A2 + B38 + and HLA-B35 + B51 + individuals, respectively, were nearly identical to the public cross-reactive TCRs, and only small amino acid insertions within both CDR3 regions (CMV B35/IPS) and even within the CDR3a region alone (FLU A2/GIL) were able to abrogate cross-reactivity. Plausibly, this exceptionally conserved TCR usage illustrates the superiority of these TCR clonotypes in generating antiviral immune responses.
The mechanisms by which the newly identified public TCRs cross-react to allo-HLA remain unknown; however, because HLA-B35 is structurally highly similar to HLA-B51 and HLA-B58/B57, and HLA-B35 and HLA-B51 present a similar peptide repertoire (30, 31) , the CMV-B35/ IPS cross-reactivity against HLA-B51 and HLA-B58/B57 may be explained by structural mimicry. Structural mimicry between an allo-and viral epitope is the most described mechanism of TCR cross-reactivity and underlies EBV B8/FLR cross-reactivity against HLA-B*44:02 as well as HLA-B*35:01 (32, 33) . Both FLU A2/GIL and VZV A2/ALW public cross-reactivities were directed against allo-HLA antigens with only little similarity to the cognate HLA antigen. Although this does not exclude structural mimicry (after all, HLA-B*08:01 and HLA-B*44:02 show substantial polymorphism and divergent peptide expression), the finding that FLU A2/GIL cross-reactivity appears to depend on CDR3a usage, whereas TCR docking to the cognate viral epitope depends primarily on binding of the Vb chain (34, 35) , could indicate a different mechanism for allorecognition and points toward an altered TCR docking mode, but this should be investigated further.
The strong functional difference in HLA-B51 versus HLA-B58/B57 allorecognition by CMV B35/IPS T cell clones is remarkable. A possible explanation may be different TCR affinities for these alloantigens. The small amino acid differences, for example, in the a 1 domain between HLA-B51 and HLA-B58/B57 may affect TCR binding (36) , especially because these involve the "generic" MHC class I restriction elements on positions 65, 66, and 69 (15) . These restriction elements are conserved for HLA-B35 and HLA-B51. In addition, variations in peptide presentation between HLA-B51 and HLA-B58/B57 could affect TCR avidity and lead to suboptimal or alternative TCR signaling and T cell activation in response to HLA-B58/B57 (37, 38) . However, for conclusive statements on the mechanisms behind TCR crossreactivity, the (allo)peptides presented in the cross-reactive HLA should be identified and crystal structures need to be assembled, which was beyond the scope of this research.
We recently identified FLU A2/GIL cross-reactivity to donor HLA-B38 in an HLA-A2 + renal transplant patient (39), emphasizing that (public) cross-reactivities can indeed present in a clinical setting. As one of the key endeavors in transplantation research is to predict alloreactivity, public cross-reactivity of virus-specific TCRs could provide a useful tool. However, potential predictive value will differ by public cross-reactivity. The prevalence of the public cross-reactive TCR clonotypes, and thus the percentage of patients that harbor these TCRs, greatly affects prediction. The described FLU A2/GIL public cross-reactivity against HLA-B38 is highly abundant, with 90% of FLU A2/GIL tetramerpositive individuals expressing the public HLA-B38 crossreactive TCR. In fact, this public TCR is considered the most abundant human TCR clonotype (35) . This high prevalence is facilitated by the facts that HLA-A2 is the most common HLA allele worldwide, that infection with the FLU virus occurs in virtually all individuals, and that the CD8 + T cell response to FLU is dominated by T cells that recognize the HLA-A2/GIL epitope. The CMV B35/ IPS HLA-B51 and HLA-B58/B57 cross-reactive TCR clonotypes were found in 23% of CMV B35/IPS tetramer-positive individuals. Although HLA-B35 is less predominant than HLA-A2, CMV affects approximately 40-100% of the world population and is one of the most prevailing infections after transplantation. The prevalence of the HLA-B55 cross-reactive VZV A2/ALW TCR crossreactivity remains to be established because the low precursor frequency of VZV A2/ALW tetramer-positive T cells in the peripheral blood hampers its accurate detection. Yet, VZV also affects nearly all individuals, the majority of HLA-A2 + individuals show CD8 + T cell responses against the VZV A2/ALW epitope (26) , and the Furthermore, functionality differs by cross-reactivity. CMV B35/IPS cross-reactivity against HLA-B51 and HLA-B58/B57 were both characterized by proliferation and IFN-c production, but only HLA-B51 cross-reactivity induced cytotoxicity. FLU A2/GIL T cells were able to proliferate, produce IFN-c, and exert cytotoxicity toward HLA-B38 + targets, whereas VZV A2/ALW-specific T cells expressed limited to no cytotoxicity but were able proliferate and produce IFN-c on allorecognition. Nevertheless, it is still unclear which functional characteristics of crossreactive T cells in vitro affect clinical outcome: Although cytotoxic responses may harm the allograft directly, cytokine production could harm the allograft indirectly by inducing an inflammatory environment (40) . In addition, one should keep in mind that functionality may differ in response to different cell types (tissue specificity), as shown for public EBV-B8/FLR cross-reactivity to allo-HLA-B*44:02 (41). When the cross-reactive allopeptide has a restricted tissue distribution, (public) TCR crossreactivity may be restricted to specific organs, whereas if it is expressed in multiple cell types, it could have broader implications for organ transplantation. In our experiments, there were no indications of tissue specificity of CMV B35/IPS cross-reactivity against HLA-B51 or VZV A2/ALW cross-reactivity against HLA-B55. HLA-B38 cross-reactive FLU A2/GIL T cells, however, appeared less potent in lysing PTECs compared with HUVECs, EBV-LCLs, and PHA blasts, suggesting there may be a certain degree of tissue specificity.
Furthermore, precursor frequencies should be determined because they could affect clinical outcome. Unlike low precursor frequencies, high precursor frequencies of alloreactive memory T cells are associated with impaired tolerance induction and contribution to graft rejection and graft-versus-host disease (42-46); therefore, cross-reactive T cell precursor frequencies strongly determine alloreactivity predictive value and should be determined by individual. Of note, precursor frequencies of virusspecific T cells have been shown to be subject to some fundamental principles that apply to most individuals and that could aid in initial risk estimation. FLU-specific memory T cells, for example, compose a small proportion of the T cell repertoire, possibly due to clearance of the virus after infection. CMV-specific memory T cells, in contrast, make up a substantial part of the CD8 + T cell repertoire (47) , likely because CMV is (like EBV) a herpesvirus that latently persists after infection. In addition, they have been shown to dominate T cell repopulation following lymphodepletion (48) and are even suggested to promote solid organ rejection (49) . Despite VZV also being a persistent virus, the precursor frequency of VZV A2/ALW-specific memory T cells is low, perhaps due to VZV "hiding" from the immune system in nerve cells. Nevertheless, the precursor frequency of HLA-B55 crossreactive VZV A2/ALW T cells could increase as a result of routine vaccination against VZV in transplantation recipients. Indeed, one of the HLA-B55 cross-reactive VZV A2/ALW T cell clones studied in this paper (clone 12) was derived from a transplant recipient that was vaccinated against VZV (22) . In addition, adoptive transfer of enriched virus-specific T cells may also introduce crossreactive virus-specific T cells at high precursor frequencies.
In conclusion, we were able to identify three novel public cross-reactivities of virus-specific memory T cells that were from a small cohort of individuals and that were subjected to a restricted number of known dominant viral epitopes and tetramers. It is expected that this research is only the tip of the iceberg-that public cross-reactivity of virus-specific T cells is much more common than anticipated. Increasing the knowledge concerning public cross-reactivities could benefit the prediction of antidonor reactivity, enable monitoring of potentially harmful alloresponses, and ultimately support clinical decision making.
